Oxford BioTherapeutics?(OBT) is a leading international biotechnology company focused on delivering innovative and cost-effective first-in-class medicines to fulfill major unmet patient needs in the field of cancer. OBT is developing cutting-edge antibody-based cancer medicines, with integrated diagnostics, against novel targets that it has discovered through its unique OGAP? proteomic database.
OBT has access to the most advanced antibody technologies and expertise through its partnerships with many of the world leaders in antibody development, including Seattle Genetics, BMS (Medarex), Amgen, Alere (formerly Biosite) and BioWa, and through its development alliances with GlaxoSmithKline and Sanofi. OBT?s diagnostic collaboration with Alere also provides the opportunity to develop tailored diagnostics for OBT?s therapeutic products.
These unique partnerships have enabled OBT to convert its world leading capabilities in the discovery of novel oncology targets into a highly attractive pipeline of therapeutic antibodies, which includes various?antibody and antibody drug conjugate (ADC) programs, each of which addresses a?different cancer indication via a different novel oncology target.
94a Innovation Drive